Jasper Therapeutics, Inc. (JSPR)
| Market Cap | 23.00M -71.3% |
| Revenue (ttm) | n/a |
| Net Income | -75.80M |
| EPS | -3.95 |
| Shares Out | 28.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 417,441 |
| Open | 0.9161 |
| Previous Close | 0.9590 |
| Day's Range | 0.8050 - 0.9299 |
| 52-Week Range | 0.6230 - 7.1900 |
| Beta | 3.08 |
| Analysts | Buy |
| Price Target | 9.19 (+1,018.69%) |
| Earnings Date | May 14, 2026 |
About JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for JSPR stock is "Buy." The 12-month stock price target is $9.19, which is an increase of 1,018.69% from the latest price.
News
Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital
RBC Capital lowered the firm’s price target on Jasper Therapeutics (JSPR) to $3 from $4 and keeps a Sector Perform rating on the shares. The firm continues to believe that…
Jasper Therapeutics downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Jasper Therapeutics (JSPR) to Hold from Buy without a price target The company is “now at a critical juncture,” the analyst tells investors in a research note.
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
Evercore ISI lowered the firm’s price target on Jasper Therapeutics (JSPR) to $7 from $12 and keeps an Outperform rating on the shares. The firm adjusted targets for its small-to-mid…
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)
“Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,” said Jeet Mahal, President and CEO of…
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibo...
Jasper Therapeutics assumed with a Neutral at UBS
UBS assumed coverage of Jasper Therapeutics (JSPR) with a Neutral rating and $1.50 price target UBS sees a balanced risk-reward over the next 12 months with competitive uncertainties, but dose…
Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Briquilimab showed rapid, deep disease control in urticaria and asthma studies, with a favorable safety profile and differentiated mechanism. Phase II-B/III trials in CSU and CIndU are planned, with dose selection focused on balancing efficacy and safety. Equity financing is likely for upcoming studies.
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
Jasper Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Mike King initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $17 price target
Jasper Therapeutics Transcript: Study Result
Updated BEACON and open-label extension data show briquilimab delivers rapid, deep, and durable disease control in CSU and CIndU, with a favorable safety profile and low incidence of adverse events. Results support advancing to a phase 2b study in the second half of 2026.
Jasper Therapeutics reports updated data from briquilimab studies
Jasper Therapeutics (JSPR) is reporting positive updated clinical data from Jasper’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU, as well as from the open label...
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points
Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO
Jasper Therapeutics (JSPR) announced that its Board of Directors has appointed Jeet Mahal as President and CEO, and a member of the Board, effective January 5. Mahal succeeds Ronald Martell,…
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study ...
3 Penny Stocks to Watch Now, 12/4/25
Fitell Corporation ($FTEL), Jasper Therapeutics ($JSPR), and Boqii Holding ($BQ) are the 3 Penny Stocks to watch on December 4. 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are sha...
Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Briquilimab clinical programs in CSU and asthma advanced, with new data revealing misdiagnosis in some CSU patients and strong efficacy signals in asthma. Enhanced screening and trial designs are in place, with major data and development milestones expected in early 2024.
Jasper Therapeutics Transcript: Study Result
Unexpected lack of efficacy in BEACON trial U.S. cohorts was attributed to misdiagnosis, not drug failure, with robust safety and efficacy confirmed in properly diagnosed CSU patients. ATESIAN study data showed strong proof of concept for briquilimab in asthma, supporting further development.
Jasper Therapeutics reports data from ETESIAN Phase 1b study
Jasper Therapeutics (JSPR) reported positive preliminary clinical data from Jasper’s ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma. A single subcutaneou...
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, ...
Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
No drug quality issues were found after anomalous patient responses; focus shifted to patient selection and site conduct. New enrollment and stricter criteria are in place, with major data updates from CSU, asthma, and Sindhu studies expected in early Q1 next year.
Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference
Briquilimab, a mast cell-depleting antibody, shows promising efficacy and safety in urticaria trials, with key data updates and investigation results expected in Q4 and early Q1. Phase IIb in CSU is planned for mid-2026, and the company has cash runway into Q3 2025.
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)
“With a number of data events expected in the coming months, we remain focused on advancing our programs in chronic urticaria and continue to believe that briquilimab has the potential…
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...